FDA Seeks Applications for Testosterone Use in Men With Low Libido and Levels Below 300
Updated
Updated · Scientific American · May 10
FDA Seeks Applications for Testosterone Use in Men With Low Libido and Levels Below 300
2 articles · Updated · Scientific American · May 10
April’s FDA move invited drugmakers to seek approval for testosterone in men with low libido and unexplained low testosterone, widening access beyond the current US limit for classical hypogonadism tied to known medical causes.
The shift follows a December expert panel that called testosterone a broader preventive-health tool, though the agency has not adopted other ideas such as routine testing for all men or ending its controlled-substance status.
TRAVERSE, a trial of about 5,200 men, helped ease safety concerns by finding no higher rate of major cardiovascular events with therapeutic dosing, prompting the FDA last year to remove a heart-risk warning.
Evidence for benefit remains narrower than advocates claim: a subanalysis of roughly 1,100 men found sexual activity rose 25% more with testosterone than placebo, while mood, energy and cognition showed little clear improvement.
High-dose misuse remains a major concern, with risks including infertility, cardiomyopathy and dependence; researchers say proving broader preventive benefits would require a large trial of about 10,000 older men followed for at least four years.
With conflicting studies, what is the true long-term cardiovascular risk of testosterone therapy?
Is expanding testosterone access a preventive health revolution or the next public health gamble?
Is low testosterone a disease to be treated, or a symptom of an unhealthy modern lifestyle?
FDA Moves to Expand TRT Indications: New Evidence and Regulatory Pathways for Men’s Sexual Health
Overview
In April 2026, the FDA launched an initiative to expand the approved uses of testosterone replacement therapy (TRT), reflecting a growing recognition of sexual health as an important part of overall well-being. This move is seen as a chance to use new scientific knowledge and potentially offer more treatment options for men with hypogonadism. The FDA and health leaders are encouraging manufacturers to innovate and work together, asking them to provide high-quality evidence to support expanding TRT indications. With this approach, men affected by hypogonadism could have more choices for improving their quality of life.